Skip to content
Open access · CC-BY via OpenAlex

Anti-Atherogenic Actions of Pomegranate Polyphenol Punicalagin and Its Metabolites: In Vitro Effects on Vascular Cells and In Vivo Atheroprotection by Urolithin A via Anti-Inflammatory and Plaque-Stabilising Mechanisms

Sulaiman Alalawi, Daniah Rifqi, Alaa Alhamadi, Reem Alotibi, Fahad Alradi, Nouf Alshehri, Yee‐Hung Chan, Jing Chen, Faizah Albalawi, Sarab Taha, Nabras Al-Mahrami, Irina A. Guschina, Timothy R. Hughes, Dipak P. Ramji

Antioxidants · 2026

Abstract

Nutraceuticals are emerging as promising agents for the prevention and treatment of atherosclerosis, particularly in light of the limitations associated with current pharmacotherapies. Pomegranate-derived polyphenols, especially punicalagin (PC), possess multiple cardioprotective properties. However, their direct biological effects are constrained by poor absorption and low bioavailability. Instead, many of their actions are mediated by gut microbiota-derived metabolites known as urolithins. Despite this, the roles of PC and its metabolites in atherosclerosis remain inadequately defined. The objective of this study was to investigate the anti-atherogenic effects and underlying mechanisms of PC and its major metabolites-ellagic acid and urolithins A, B, C, and D-using in vitro and in vivo approaches. In vitro, these compounds broadly inhibited key pro-atherogenic processes in macrophages and endothelial cells, including reactive oxygen species production and inflammatory gene expression, with notable metabolite-specific differences. Urolithin A (UA), identified as the most effective compound, was further evaluated in LDL receptor-deficient mice fed a high-fat diet. UA supplementation improved peripheral blood immune cell profile, reduced atherosclerotic plaque burden and inflammation, and enhanced markers of plaque stability. RNA sequencing of the thoracic aorta revealed key molecular pathways underlying the protective actions of UA. Collectively, these findings highlight the therapeutic potential of PC-derived metabolites, particularly UA, in combating atherosclerosis and support the need for future human clinical studies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/antiox15040507
Canonical
link ↗
Fetched
2026-10-12 MST

Cite this

APA
Alalawi, S., Rifqi, D., Alhamadi, A., Alotibi, R., Alradi, F., Alshehri, N., Chan, Y., Chen, J., Albalawi, F., Taha, S., Al-Mahrami, N., Guschina, I.A., Hughes, T.R., &amp; Ramji, D.P. (2026). Anti-Atherogenic Actions of Pomegranate Polyphenol Punicalagin and Its Metabolites: In Vitro Effects on Vascular Cells and In Vivo Atheroprotection by Urolithin A via Anti-Inflammatory and Plaque-Stabilising Mechanisms. <em>Antioxidants</em>. https://doi.org/10.3390/antiox15040507
Vancouver
Alalawi S, Rifqi D, Alhamadi A, Alotibi R, Alradi F, Alshehri N, et al. Anti-Atherogenic Actions of Pomegranate Polyphenol Punicalagin and Its Metabolites: In Vitro Effects on Vascular Cells and In Vivo Atheroprotection by Urolithin A via Anti-Inflammatory and Plaque-Stabilising Mechanisms. Antioxidants. 2026. doi:10.3390/antiox15040507.
BibTeX
@article{sulaiman2026AntiAt, title = {Anti-Atherogenic Actions of Pomegranate Polyphenol Punicalagin and Its Metabolites: In Vitro Effects on Vascular Cells and In Vivo Atheroprotection by Urolithin A via Anti-Inflammatory and Plaque-Stabilising Mechanisms}, author = {Sulaiman Alalawi and Daniah Rifqi and Alaa Alhamadi and Reem Alotibi and Fahad Alradi and Nouf Alshehri and Yee‐Hung Chan and Jing Chen and Faizah Albalawi and Sarab Taha and Nabras Al-Mahrami and Irina A. Guschina and Timothy R. Hughes and Dipak P. Ramji}, journal = {Antioxidants}, year = {2026}, doi = {10.3390/antiox15040507}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings